Exact Sciences stock price target lowered to $66 by TD Cowen after blood test setback

Published 07/08/2025, 15:48
Exact Sciences stock price target lowered to $66 by TD Cowen after blood test setback

Investing.com - TD Cowen has reduced its price target on Exact Sciences (NASDAQ:EXAS) to $66.00 from $75.00 while maintaining a Buy rating on the stock. Currently trading at $41.82, the stock sits well below analyst targets ranging from $46 to $90, according to InvestingPro data.

The price target adjustment comes despite Exact Sciences reporting strong second-quarter results, which TD Cowen described as the "best Cologuard quarter in a while," featuring significant margin beats and raised guidance. The company maintains a healthy 69% gross profit margin and has demonstrated solid 12.6% revenue growth over the last twelve months.

The approximately 20% post-market decline in Exact Sciences shares was attributed to disappointing colorectal cancer (CRC) blood test data, which overshadowed the otherwise positive quarterly performance.

In response to the blood test setback, Exact Sciences has signed a deal with competitor Freenome to gain access to their blood-based CRC test and pipeline, with FDA approval anticipated in 2026.

TD Cowen indicated that the sell-off in Exact Sciences stock appears "overdone" given the company’s strong quarterly performance and proactive steps to address the blood test challenges.

In other recent news, Exact Sciences Corporation reported its second-quarter 2025 earnings, surpassing analysts’ expectations. The company posted an earnings per share (EPS) of -$0.01, which was significantly better than the forecasted -$0.13, resulting in a 92.31% EPS surprise. Revenue also exceeded projections, reaching $811.1 million compared to the expected $773.8 million, marking a 4.82% surprise. Piper Sandler has reiterated its Overweight rating on Exact Sciences, maintaining a price target of $70.00. The firm highlighted Exact Sciences’ strong position in colorectal cancer screening, noting a shift toward noninvasive detection methods in the market. These recent developments underscore Exact Sciences’ positive financial performance and its continued influence in the medical diagnostics field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.